natgillin/translations-raw huggingface dataset:
• Marketing authorisation under exceptional circumstances The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the marketing authorisation under exceptional circumstances as further explained in the European Public Assessment Report. 
Odbor za zdravila za uporabo v humani medicini (CHMP) po obravnavi vloge meni, da je razmerje med tveganji in koristmi ugodno, da lahko priporoči izdajo dovoljenja za promet z zdravilom v izjemnih okoliščinah, kot je podrobneje razloženo v evropskem javnem poročilu o oceni zdravila.
Annex IV Conclusions on the granting of the marketing authorisation under exceptional circumstances presented by the European Medicines Agency 
Sklepne ugotovitve o pridobitvi dovoljenja za promet z zdravilom v izjemnih okoliščinah, ki jih je predstavila evropska agencija za zdravila
Implementation of the agreement by the Member States: 
Izvajanje sporazuma v državah članicah:
25 July 2013 
25. julij 2013
25 June 2013 
25. junij 2013
May 2013 CMDh meeting 
Zasedanje skupine CMDh maja 2013
In both studies, the main measure of effectiveness was the number of patients with no sign of inflammation after two weeks. 
V obeh študijah je bilo glavno merilo učinkovitosti število bolnikov, pri katerih po dveh tednih ni bilo znakov vnetja.
The European Commission granted a marketing authorisation valid throughout the European Union for Yellox on 18 May 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Yellox, veljavno po vsej Evropski uniji, izdala 18. maja 2011.
What measures are being taken to ensure the safe and effective use of Yellox? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Yellox?
This is a summary of the European public assessment report (EPAR) for Yellox. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Yellox.
The full EPAR for Yellox can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Yellox je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Medicines Agency decided that Yellox's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Evropska agencija za zdravila je sklenila, da so koristi zdravila Yellox večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
If more than one eye medicine is being used, they should be given at least five minutes apart. 
Če bolnik uporablja več vrst kapljic za oči, je treba zdravila uporabiti v razmiku najmanj pet minut.
Other information about Yellox 
Druge informacije o zdravilu Yellox
For more information see the package leaflet. 
Za več informacij glejte navodilo za uporabo.
In the second study, the figures were: 63% (124 out of 198) for patients treated with Yellox and 40% (39 out of 98) for those treated with placebo. 
V drugi študiji so bili deleži naslednji: 63 % (124 od 198) bolnikov, zdravljenih z zdravilom Yellox, in 40 % (39 od 98) bolnikov, ki so prejemali placebo.
The most common or most important side effects seen with Yellox are abnormal sensation in eye (0.5%), mild or moderate erosion of the cornea (the transparent layer in front of the eye) (0.4%), eye pruritus (itching) (0.4%), eye pain (0.3%) and eye redness (0.3%). 
Najpogostejši ali najpomembnejši neželeni učinki, opaženi pri zdravilu Yellox, so nenormalen občutek v očesu (0,5 % bolnikov), blaga ali zmerna erozija roženice (prozorne plasti na prednji strani očesa) (0,4 %), očesni pruritus (srbenje) (0,4 %), bolečina v očesu (0,3 %) in rdečica očesa (0,3 %).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yellox have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Yellox upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
It works by blocking an enzyme called cyclo-oxygenase, which produces prostaglandins, substances that are involved in the inflammation process. 
Deluje tako, da zavira encim, imenovan ciklooksigenaza, ki proizvaja prostaglandine, tj. snovi, ki sodelujejo pri vnetnih procesih.
In one study, 66% of patients treated with Yellox (104 out of 158) had no signs of inflammation after two weeks compared with 48% of patients receiving placebo (35 out of 73). 
V eni študiji 66 % (104 od 158) bolnikov, zdravljenih z zdravilom Yellox, po dveh tednih ni kazalo znakov vnetja v primerjavi z 48 % (35 od 73) bolnikov, ki so prejemali placebo.
What are the risks associated with Yellox? 
Kakšna tveganja so povezana z zdravilom Yellox?
What benefits of Yellox have been shown during the studies? 
Kakšne koristi je zdravilo Yellox izkazalo v študijah?
It must not be used in patients who get asthma attacks, urticaria (itchy rash) or acute rhinitis (stuffy and runny nose) from taking acetylsalicylic acid (aspirin) or other NSAIDs. 
Ne sme se uporabljati pri bolnikih, ki dobijo napade astme, urtikarijo (srbeč izpuščaj) ali akutni rinitis (zamašen nos ali izcedek iz nosu), če vzamejo acetilsalicilno kislino (aspirin) ali druga nesteroidna protivnetna zdravila.
For more information about treatment with Yellox, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Yellox preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Why is Yellox approved? 
Zakaj je bilo zdravilo Yellox odobreno?
Yellox was found to be more effective than placebo (a dummy treatment) at relieving inflammation in the eye following cataract surgery in two main studies involving a total of 527 patients undergoing cataract surgery. 
Zdravilo Yellox je bilo učinkovitejše od placeba (zdravila brez zdravilne učinkovine) pri lajšanju očesnega vnetja po operativni odstranitvi katarakte v dveh glavnih študijah, v katerih je sodelovalo skupno 527 bolnikov, pri katerih so opravili ta poseg.
What is Yellox and what is it used for? 
Kaj je zdravilo Yellox in za kaj se uporablja?
The active substance in Yellox, bromfenac, is a non-steroidal anti-inflammatory drug (NSAID). 
Zdravilna učinkovina v zdravilu Yellox, bromfenak, je nesteroidno protivnetno zdravilo (NSAID).
It is not intended to provide practical advice on how to use Yellox. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
For practical information about using Yellox, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Yellox naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects reported with Yellox, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Yellox, glejte navodilo za uporabo.
By reducing the production of prostaglandins in the eye, Yellox can reduce the inflammation caused by eye surgery. 
Zdravilo Yellox lahko s tem, ko zmanjša izdelavo prostaglandinov, zmanjša vnetje, ki ga povzroča operativni poseg na očeh.
Yellox must not be used in people who are hypersensitive (allergic) to bromfenac, to any of the other ingredients or to other NSAIDs. 
Zdravila Yellox ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) bromfenak, katero koli drugo sestavino zdravila ali na druga nesteroidna protivnetna zdravila.
Yellox is available as an eye drop solution and the recommended dose is one drop into the affected eye(s) twice a day. 
Zdravilo Yellox je na voljo kot raztopina kapljic za oko, priporočeni odmerek pa je ena kapljica v prizadeto oko (prizadeti očesi) dvakrat na dan. Zdravljenje se začne dan po operaciji katarakte in traja dva tedna.
Yellox is a medicine used in adults to treat inflammation in the eye that can occur after an operation to remove a cataract (clouding of the lens). 
Zdravilo Yellox se uporablja za zdravljenje vnetja očesa pri odraslih, do katerega lahko pride po operaciji katarakte (zameglitve očesne leče).
How does Yellox work? 
Kako zdravilo Yellox deluje?
How is Yellox used? 
Kako se zdravilo Yellox uporablja?
Yellox contains the active substance bromfenac. 
Zdravilo vsebuje zdravilno učinkovino bromfenak.
(see section 4.4). 
(Glejte poglavje 4.4.)
This should be considered when interpreting laboratory data. 
To je treba upoštevati pri analizi laboratorijskih podatkov.
Take your next dose at the normal time. 
Naslednji odmerek vzemite ob običajnem času.
Elderly: Same dosage as for adults. 
Starejši bolniki: Isti odmerek kot za odrasle.
Choose a time that is convenient for you and take your tablet at this time each day. 
Izberite si čas, ki vam ustreza, in jih jemljite ob tem času vsak dan.
The food-interaction study was not performed according to the CHMP guidelines. 
Raziskava o medsebojnem delovanju s hrano ni bila izvedena v skladu s smernicami CHMP.
Hertfordshire, SG1 4SZ United Kingdom Tel 00 44 207 612 7612 Fax 00 44 207 612 7620 
Hertfordshire, SG1 4SZ Združeno kraljestvo Tel 00 44 207 612 7612 Faks 00 44 207 612 7620
Symptomatic treatment. 
Simptomatsko zdravljenje.
If this happens do not worry but make sure that you do not drive, operate machinery or carry out any activity which might be dangerous should you feel faint. 
Če se to zgodi, ne skrbite, vendar pa zagotovite, da ne boste vozili avtomobila, upravljali strojev ali opravljali dejavnosti, ki bi lahko bile nevarne, če bi čutili omedlevico.
The tablets can be taken with or without food. 
Tablete se lahko jemljejo s hrano ali brez nje.
Cellulose, microcrystalline Povidone K 29-32 
Celuloza, mikrokristalna Povidon K 29-32
You should contact your doctor immediately or go to the nearest casualty department. 
Takoj obvestite zdravnika ali obiščite najbližji nezgodni oddelek.
Remember to take the pack and any remaining tablets with you. 
S seboj vzemite pakiranje in morebitne preostale tablete.
Close control of blood pressure. 
Temeljit nadzor krvnega tlaka.
Very common (>1/10); common (>1/100, <1/10); uncommon (>1/1, 000, <1/100); rare (>1/10, 000, <1/1, 000); very rare (<1/10, 000), including isolated reports 
Zelo pogosti (> 1/10), pogosti (> 1/100, < 1/10), občasni (> 1/1000, < 1/100), redki (> 1/10.000, < 1/1000), zelo redki (< 1/10.000), vključno s posameznimi poročili.
Some patients may experience impaired ability to react. 
Pri nekaterih bolnikih se sposobnost reagiranja lahko zmanjša.
Particular caution: 
Posebno opozorilo:
In hypertensive patients both conditions are treated concomitantly. 
Pri hipertenzivnih bolnikih obe bolezni zdravimo hkrati.
When you start taking your tablets, make sure that your senses are not affected before you drive or operate machinery. 
Ko začnete jemati tablete, se prepričajte, da ne vplivajo na vaše čute, preden vozite avtomobil ali upravljate stroje.
The tablets must be swallowed whole with a sufficient amount of liquid. 
Tablete je treba pogoltniti cele z zadostno količino tekočine.
The occurrence of adverse reactions are mainly due to the pharmacological properties of the medicinal product. 
Pojav neželenih učinkov je večinoma posledica farmakoloških lastnosti zdravila.
The tablets should not be chewed, divided or crushed. 
Tablete se ne smejo žvečiti, prepoloviti ali zdrobiti.
• if you suffer from diabetic autonomic neuropathy, a disease associated with diabetes which affects your nervous system. 
• če imate diabetično avtonomno nevropatijo, bolezen, povezano s sladkorno boleznijo, ki vpliva na živčevje;
Doxazosin is one of a group of medicines called alpha-blockers. 
Doksazosin spada v skupino zdravil, imenovanih alfa blokatorji.
- It is unlikely that the potential differences observed between the reference product and the generic versions influence the information in the Summary of Product Characteristics (SPC). 
- Ni verjetno, da bi morebitne razlike, opažene med referenčnim zdravilom in generičnimi izdelki, vplivale na informacije v Povzetku glavnih značilnosti zdravila (SPC),
Taking other medicines Tell your doctor if you are already taking any of the following as they may interact with your medicine: 
Povejte zdravniku, če že jemljete katero koli izmed naslednjih zdravil, ker lahko medsebojno delujejo z vašim zdravilom:
The tablets can be taken at any time of the day and before, during or after meals. 
Tablete lahko vzamete kadar koli čez dan, med obroki ali po njih.
Doxazosin has shown to be an effective blocker of 1A subtype of alpha-adrenoceptors which make up more than 70% of the adrenergic subtypes in prostate. 
Doksazosin je učinkovit blokator podtipa 1A alfa-adrenergičnih receptorjev, ki tvorijo več kot 70 % adrenergičnih podtipov v prostati.
They should be informed about the potential risk for injuries and measures of precaution to minimise orthostatic symptoms. 
Treba jih je opozoriti na morebitno tveganje poškodb in obvestiti o ukrepih za zmanjševanje ortostatskih simptomov.
6 FURTHER INFORMATION 
6 DODATNE INFORMACIJE
Doxazosin has a minor or moderate influence on the ability to drive and use machines, especially at the beginning of therapy. 
Doksazosin ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji, zlasti na začetku zdravljenja.
Children and adolescents: Doxazosin is not recommended for use in children and adolescents due to a lack of clinical experience. 
Otroci in mladostniki: Uporaba doksazosina pri otrocih se zaradi pomanjkanja kliničnih izkušenj ne priporoča.
Additionally, doxazosin improves insulin sensitivity in patients with impaired sensitivity to insulin, but also concerning this finding the clinical relevance is still uncertain. 
Poleg tega doksazosin poveča občutljivost za insulin pri bolnikih z okvarjeno občutljivostjo za insulin, vendar tudi klinični pomen teh ugotovitev še ni znan.
Doxazosin is not considered appropriate as first-line treatment, this does not exclude the second- or third-line use in combination with other types of antihypertensives. 
Doksazosin ni primeren kot prvo zdravljenje, vendar to ne izključuje uporabe pri drugem ali tretjem zdravljenju v kombinaciji z drugimi antihipertenzivi.
The observed differences in Tmax are modest and the Cmax of the test tablet is not higher than the innovator tablet. 
Opažene razlike v Tmax so zmerne in Cmax testnih tablet ni višji kot v originatorjevem zdravilu.
A dosage regime of 82 mg/kg/day (8 times the human exposure) was associated with reduced foetal survival. 
Odmerki 82 mg/kg/dan (8-kratna izpostavljenost pri človeku) so bili povezani z zmanjšanim preživetjem fetusov.
Very rare (affecting less than one person in 10,000): a reduction in red and white cells in the blood and an increase in urea and creatinine levels in the blood. 
Zelo redki (pojavijo se pri manj kot eni osebi od 10.000): zmanjšanje števila eritrocitov in levkocitov v krvi ter zvišanje ravni uree in kreatinina v krvi.
• if you are allergic (hypersensitive) to doxazosin or any of the other ingredients of Doxazosin Retard 
• če ste preobčutljivi za (alergični na) doksazosin ali katero koli sestavino zdravila Doxazosin Retard
If these symptoms persist or become a problem please contact your doctor. 
Če ti simptomi ne izginejo ali postanejo težava, se posvetujte z zdravnikom.
Your doctor may wish to increase your dose to 8 mg per day. 
Zdravnik bo morda povečal odmerek na 8 mg na dan.
This helps to lower blood pressure. 
Tako se zniža krvni tlak.
Butylhydroxytoluene (E321) α-Tocopherol 
Butilhidroksitoluen (E 321) α-tokoferol
On initiation of therapy or increasing of dose the patient should be monitored to minimise the potential for postural effects, e.g. hypotension and syncope. 
Na začetku zdravljenja ali ob povečanju odmerka je treba bolnika opazovati, da bi zmanjšali morebitno tveganje posturalnih učinkov, npr. hipotenzije in sinkope.
You may feel faint or dizzy when standing up from a sitting or lying position especially at the beginning of your treatment or if you restart your treatment after a break. 
Morda boste čutili omedlevico ali vrtoglavico ob vstajanju iz sedečega ali ležečega položaja, zlasti na začetku zdravljenja ali po nadaljevanju zdravljenja po premoru.
Common : apathia 
Pogosti: apatija
Very rare : increase of serum creatinine. 
Zelo redki: zvišane vrednosti kreatinina v serumu
• if you have problems with your heart or a history of heart disease 
• če imate težave s srcem ali ste v preteklosti imeli srčno bolezen;
Doxazosin is contraindicated during lactation as the medicinal product accumulates in the milk of lactating rats (see section 5.3) and there is no information about the excretion of the medicinal product into human breast milk. 
Doksazosin je med dojenjem kontraindiciran, ker se zdravilo kopiči v mleku doječih podgan (glejte poglavje 5.3), o izločanju zdravila v mleko pri človeku pa ni podatkov.
Arrow Generics Limited, Unit 4/5 Willsborough Cluster, Clonshaugh Industrial Estate, Clonshaugh, Dublin 17, Republic of Ireland. 
Arrow Generics Limited, Unit 4/5 Willsborough Cluster, Clonshaugh Industrial Estate, Clonshaugh, Dublin 17, Republika Irska.
If you become pregnant whilst taking this medicine you should contact your doctor as soon as possible. 
Če med jemanjem tega zdravila zanosite, čim prej povejte zdravniku.
Pack sizes: 28, 30, 56, 98, and 100 prolonged-release tablets 
Velikosti pakiranj: 28, 30, 56, 98 in 100 tablet s podaljšanim sproščanjem.
Patients with renal impairment: Since there is no change in pharmacokinetics in patients with impaired renal function, and since there are no signs that doxazosin aggravates existing renal impairment, the usual dose can be used in these patients (see section 4.4). 
Bolniki z ledvično okvaro: Pri bolnikih z ledvično okvaro ni sprememb farmakokinetike in ni znakov, da doksazosin poslabša obstoječo ledvično okvaro, zato se pri teh bolnikih lahko uporabi običajni odmerek (glejte poglavje 4.4).
Patients with acute heart diseases: 
Bolniki z akutnimi srčnimi boleznimi:
The plasma elimination is biphasic with the terminal elimination half-life being 22 hours and hence this provides the basic for once daily dosing 
Izločanje iz plazme je dvofazno, končni razpolovni čas izločanja je 22 ur, kar omogoča odmerjanje enkrat dnevno.
Doxazosin is highly bound to plasma proteins (98%). 
Doksazosin se v veliki meri veže na beljakovine v plazmi (98 %).
Blood and the lymphatic system disorders: Very rare : Reduction of erythrocytes, leucocytes and thrombocytes 
Bolezni krvi in limfatičnega sistema: Zelo redki: zmanjšanje števila eritrocitov, levkocitov in trombocitov
• if you have liver disease or you are taking medicines to control the way your liver works such as cimetidine or if you are undergoing dialysis 
• če imate bolezen jeter ali jemljete zdravila za nadzor delovanja jeter, kot je cimetidin, ali ste na dializi;
This medicinal product is authorised in the Member States of the EEA under the following names: 
Zdravilo je pridobilo dovoljenje za promet v državah članicah EGP pod naslednjimi imeni: [Izpolni država članica]
Adults: Usually 4 mg doxazosin once daily. 
Odrasli: Običajno 4 mg doksazosina enkrat dnevno.
Studies in lactating rats given a single oral dose of radioactive doxazosin gave an accumulation in the breast milk with a maximum concentration of about 20 times greater than the maternal plasma concentration. 
V študijah na doječih podganah, ki so jim dali enkratni peroralni odmerek radioaktivnega doksazosina, so ugotovili kopičenje v mleku, kjer je bila najvišja koncentracija približno 20-krat višja od koncentracije v plazmi matere.
- Essential hypertension - Symptomatic treatment of benign prostatic hyperplasia. 
- Esencialna hipertenzija, - simptomatsko zdravljenje benigne hiperplazije prostate.
Your medicine is in the form of prolonged-release tablets. 
Vaše zdravilo je v obliki tablet s podaljšanim sproščanjem.
• if you have or have had in the past any form of obstruction of the digestive tract. 
• če imate ali ste v preteklosti imeli kakršno koli obliko zapore prebavil.
In patients treated for benign prostatic hyperplasia and without hypertension mean blood pressure changes are small, but hypotension, dizziness, fatigue occur in 10 - 20% of the patients and oedema and dyspnoea occur in less than 5% of patients. 
Pri bolnikih, ki se zdravijo zaradi benigne hiperplazije prostate in ki niso hipertenzivni, so spremembe srednje vrednosti krvnega tlaka majhne, vendar pri 10-20 % bolnikov pride do hipotenzije, vrtoglavice in utrujenosti, pri manj kot 5 % pa do edema in dispneje.
• if you have a serious kidney disorder (anuria or progressive renal insufficiency) 
• če imate resno bolezen ledvic (anurijo ali progresivno ledvično okvaro);
The majority of patients are controlled on the initial dose of 4 mg doxazosin. 
Pri večini bolnikov za nadzor bolezni zadostuje začetni odmerek 4 mg doksazosina.
They are used to treat high blood pressure or the symptoms caused by enlargement of the prostate gland in men. 
Lahko se uporablja za zdravljenje povišanega krvnega tlaka ali simptomov, ki jih povzroča povečanje prostate pri moških.
Doxazosin should be used with care in patients with Diabetic Autonomic Neuropathy. 
Doksazosin je treba pri bolnikih z diabetično avtonomno nevropatijo uporabljati previdno.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODIL ZA UPORABO, KI JIH JE PREDSTAVILA EMEA
- The scope of the referral was to agree whether Doxazosin “Arrow” 4mg prolonged release tablets differ significantly with regards to the release profile from the originator product with potential for increased incidence of adverse events such as dizziness and hypotension, whether there were significant differences in performance of test batches in the single dose phase of studies 5208 and 1995 and whether the applicant has deviated from CHMP guidelines on the design of the bioequivalence studies, particularly in relation to the effect of food with concern regarding the adequate sensitivity of to detect a difference between products, 
- Namen napotitve je bil doseči soglasje o tem, ali se zdravilo Doksazosin Retard Arrow 4 mg tablete s podaljšanim sproščanjem, kar se tiče profila sproščanja, pomembno razlikuje od originatorjevega zdravila, in ali je možnost pojavov neželenih učinkov, kot so omotica in hipotenzija, morebiti povečana; nadalje ali so bile razlike v rezultatih iz študij 5208 in 1995 testnih serij pri enkratnem odmerjanju pomembne, ter končno ali se je vlagatelj oddaljil od smernic pri oblikovanju bioekvivalenčnih raziskav, zlasti kar se tiče učinka, ki bi ga lahko imela hrana na ustrezno občutljivost za zaznavanje razlik med zdraviloma.
Caution is also recommended when doxazosin is administered concomitantly with medicinal products which may influence hepatic metabolism (e.g. cimetidine). 
Previdnost je priporočljiva tudi, kadar se doksazosin uporablja sočasno z zdravili, ki vplivajo na presnovo v jetrih (npr. cimetidin).
Distribution: App. 98% of doxazosin is protein-bound in plasma. 
Porazdelitev: Približno 98 % doksazosina se veže na beljakovine v plazmi.
10 DATE OF REVISION OF THE TEXT [To be completed nationally] 
10 DATUM ZADNJE REVIZIJE BESEDILA [Izpolni država članica]
PVC/PVDC/aluminium blister. 
Pretisni omot iz PVC/PVDC/aluminija.
Administration of doxazosin in hypertensive patients causes a clinically significant reduction in blood pressure as a result of a reduction in systemic vascular resistance. 
Uporaba doksazosina pri hipertenzivnih bolnikih povzroča klinično pomembno znižanje krvnega tlaka zaradi zmanjšanja sistemskega žilnega upora.
Arrow Generics Limited, Unit 2, Eastman Way, Stevenage, Hertfordshire, SG1 4SZ, United Kingdom 
Arrow Generics Limited, Unit 2, Eastman Way, Stevenage, Hertfordshire, SG1 4SZ, Velika Britanija.